Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
5.4
Journals
Pharmaceutics
Special Issues
Advanced Nanomedicine for Central Nervous System Diseases
share announcement

Advanced Nanomedicine for Central Nervous System Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1293

Special Issue Editor

Dr. Xiaowei Dong

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy, University of North Texas Systems, Fort Worth, Texas, USA
Interests: blood–brain barrier; nanomedicine; central nervous disorders; brain penetration

Special Issue Information

Dear Colleagues,

Central nervous system (CNS) disorders are some of the most prevalent, devastating and yet poorly treated diseases. The numbers of people afflicted with CNS disorders are increasing. In addition to the complexity of CNS diseases, the lack of efficient technologies to deliver drugs into the CNS or understand CNS diseases hinders CNS treatments. Nanomedicines utilize various transport mechanisms to deliver drugs into the brain. In addition, non-invasive techniques such as ultrasound and magnetic resonance imaging can be combined with nanomedicines to enhance the treatment, imaging, and diagnostics for CNS diseases.

The goal of the Special Issue is to collect research articles and reviews to capture the current state-of-the-art of nanomedicines for CNS diseases. Studies on nanomedicines or the combination of nanomedicines with non-invasive techniques to treat and diagnose CNS diseases or to understand the pathologies of CNS diseases are welcome for submission to this Special Issue.

Dr. Xiaowei Dong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood–brain barrier
  • nanomedicine
  • central nervous disorders
  • central nervous system
  • pathology
  • diagnosis
  • non-invasive techniques
  • brain penetration
  • treatment of CNS diseases

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 4066 KiB  
Article
Rapid and Widespread Distribution of Intranasal Small Extracellular Vesicles Derived from Mesenchymal Stem Cells throughout the Brain Potentially via the Perivascular Pathway
by Weiwei Shen, Tongyao You, Wenqing Xu, Yanan Xie, Yingzhe Wang and Mei Cui
Pharmaceutics 2023, 15(11), 2578; https://doi.org/10.3390/pharmaceutics15112578 - 3 Nov 2023
Cited by 1 | Viewed by 1050
Abstract
Intranasal administration is a promising strategy to enhance the delivery of the sEVsomes-based drug delivery system to the central nervous system (CNS). This study aimed to explore central distributive characteristics of mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) and underlying pathways. Here, we [...] Read more.
Intranasal administration is a promising strategy to enhance the delivery of the sEVsomes-based drug delivery system to the central nervous system (CNS). This study aimed to explore central distributive characteristics of mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) and underlying pathways. Here, we observed that intranasal MSC-sEVs were rapidly distributed to various brain regions, especially in the subcortex distant from the olfactory bulb, and were absorbed by multiple cells residing in these regions. We captured earlier transportation of intranasal MSC-sEVs into the perivascular space and found an increase in cerebrospinal fluid influx after intranasal administration, particularly in subcortical structures of anterior brain regions where intranasal sEVs were distributed more significantly. These results suggest that the perivascular pathway may underlie the rapid and widespread central delivery kinetics of intranasal MSC-sEVs and support the potential of the intranasal route to deliver MSC-sEVs to the brain for CNS therapy. Full article
(This article belongs to the Special Issue Advanced Nanomedicine for Central Nervous System Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop